Literature DB >> 20655303

Cyclophosphamide and ascorbic acid-mediated ultrastructural and biochemical changes in Dalton's lymphoma cells in vivo.

Surya Bali Prasad1, Gabriel Rosangkima, Bonnie M Nicol.   

Abstract

Cyclophosphamide, an antineoplastic drug effective against a wide variety of cancers is cytotoxic to normal cells also. Ascorbic acid (vitamin C) at higher concentrations possesses cytotoxic effects and it can also enhance the cytotoxicity of 5-fluorouracil in a dose-dependent manner in mouse lymphoma. In the present study, effect of cyclophosphamide treatment alone and in combination with ascorbic acid in vivo on the ultrastructure and some biochemical changes in Dalton's lymphoma tumor cells were investigated. Cyclophosphamide treatment causes disappearance of cell membrane processes, thickening and reduction in the number of mitochondrial cristae as well as the manifestation of rounded shape of mitochondria. The combination treatment with ascorbic acid plus cyclophosphamide caused further changes in tumor cells showing disintegration in the cell surface membrane, disruption in the nuclear membrane and roundish mitochondria with reduction and disruption in the mitochondrial cristae. The observed ascorbic acid plus cyclophosphamide-mediated decrease in reduced glutathione (GSH) in tumor cells may play an important role in the antitumor activity of cyclophosphamide by weakening cellular antioxidant-mediated defense mechanism, thereby increasing tumor cell's susceptibility to cell death. The cyclophosphamide-mediated decrease in lactate dehydrogenase activity in tumor cells and simultaneous increase in ascites supernatant may possibly indicate alteration in the membrane permeability of tumor cells for lactate dehydrogenase as well as tumor cell injury. Further investigation should determine detailed mechanism(s) involved in cyclophosphamide-induced ultrastructural and biochemical changes in tumor cells. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655303     DOI: 10.1016/j.ejphar.2010.07.020

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Anti-tumor effects of Astragalus on hepatocellular carcinoma in vivo.

Authors:  Lian-Kun Li; Wen-Juan Kuang; Yun-Feng Huang; Han-Hong Xie; Guo Chen; Qing-Chun Zhou; Bin-Rong Wang; Li-Hong Wan
Journal:  Indian J Pharmacol       Date:  2012-01       Impact factor: 1.200

2.  Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy.

Authors:  Constance C F M J Baaten; Floor C J I Moenen; Yvonne M C Henskens; Frauke Swieringa; Rick J H Wetzels; René van Oerle; Harry F G Heijnen; Hugo Ten Cate; Graham P Holloway; Erik A M Beckers; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

3.  Cyclophosphamide and epirubicin induce high apoptosis in microglia cells while epirubicin provokes DNA damage and microglial activation at sub-lethal concentrations.

Authors:  Rafael de la Hoz-Camacho; Ana Luisa Rivera-Lazarín; Jose Manuel Vázquez-Guillen; Diana Caballero-Hernández; Edgar Mendoza-Gamboa; Ana Carolina Martínez-Torres; Cristina Rodríguez-Padilla
Journal:  EXCLI J       Date:  2022-01-10       Impact factor: 4.068

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.